Persistent Asset Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Persistent Asset Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$419K	Sell	939 -1,727	-65%	-$805K	0.16%	123
2025 Q4	$1.21M	Buy	+2,666	New	+$1.15M	0.54%	48
2025 Q3	–	Sell	-2,303	Closed	-$1.03M	–	310
2025 Q2	$1.03M	Buy	+2,303	New	+$1.06M	0.76%	39

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Persistent Asset Partners's VRTX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 65% in Q1 2026, selling an estimated $805K and leaving 939 shares worth $419K. The position accounts for 0.16% of the portfolio, ranked #123.

Persistent Asset Partners first reported a position in VRTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.21M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Persistent Asset Partners held 939 shares of Vertex Pharmaceuticals worth $419K as of Q1 2026.
Persistent Asset Partners sold 1,727 Vertex Pharmaceuticals shares in Q1 2026, an estimated $805K.
Vertex Pharmaceuticals made up 0.16% of Persistent Asset Partners's portfolio in Q1 2026, its #123 holding.
Persistent Asset Partners first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
Persistent Asset Partners's Vertex Pharmaceuticals position peaked at $1.21M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.